Vertex Pharmaceuticals
VRTXNASDAQDisease-focused small molecules, cell therapy, and gene-editing partnerships
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.
Filing figures as of June 30, 2026 · text updated 2026-04-09, 222 days ago · where each field comes from
Key figures from SEC filings
VRTX filings on EDGAR →Cash & investments
$13.64B
at June 30, 2026 (10-Q)
Quarterly operating burn
No burn
operating cash flow positive, Jan–Jun 2026
Cash runway
—
not a runway: funded by operations
Shares outstanding
253.5M
cover page of the latest filing
Read from VRTX's XBRL financial data; latest filing August 4, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Commercial.
Upcoming catalysts
Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.
Suzetrigine DPN Phase 3: Suzetrigine in Pain associated with diabetic peripheral neuropathy — primary completion
2027-05-31
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
Suzetrigine DPN open-label extension: Suzetrigine in Diabetic peripheral neuropathic pain — primary completion
2027-01-25
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
ELX/TEZ/IVA non-F508del: Elexacaftor/tezacaftor/ivacaftor in Cystic fibrosis, non-F508del genotypes — primary completion
2027-04-06
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| Trikafta | cystic fibrosis | Approved | Not disclosed | ▼ |
| Suzetrigine | acute and neuropathic pain | NDA/BLA Filed | Not disclosed | ▼ |
| Casgevy | sickle cell disease and transfusion-dependent beta thalassemia | Approved | Not disclosed | ▼ |
Analysis
Comparable companies
Sponsored
Get premium VRTX analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you